BNP-32 (B-type Natriuretic Peptide)
/ Endogenous 32-residue B-type natriuretic peptide; NPR-A agonist; ventricular myocyte sourceALIAS · B-type natriuretic peptide 1-32 · Brain natriuretic peptide · BNP · Recombinant BNP (nesiritide)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 1 by virtue of nesiritide (recombinant human BNP-32) FDA approval in 2001 for acute decompensated heart failure. BNP-32 is also the basis of the BNP and NT-proBNP assays that are foundational biomarkers in heart-failure diagnosis and prognosis. The native peptide page describes the parent molecule whose recombinant form became the FDA-approved product.
BNP-32 is a 32-residue peptide of the natriuretic peptide family released primarily from ventricular cardiomyocytes in response to wall stress and stretch. The mature peptide is generated by furin / corin cleavage of proBNP-108, which simultaneously produces the inert N-terminal fragment NT-proBNP (residues 1-76) - the analyte preferred for many clinical assays because of its longer half-life. Like ANP, BNP-32 contains a 17-residue disulfide-stabilised ring required for receptor engagement.
BNP-32 signals through NPR-A (the same membrane guanylyl cyclase as ANP) producing cyclic GMP, and is cleared by NPR-C and by neprilysin-mediated proteolysis. Neprilysin inhibition is the basis for the sacubitril/valsartan combination drug class that augments endogenous BNP signalling in chronic heart failure.
The functional profile - natriuresis, diuresis, vasodilation, and suppression of renin-angiotensin-aldosterone and sympathetic activity - parallels ANP but with relative cardiac-source predominance. The recombinant peptide nesiritide was developed and approved as an intravenous infusion for symptomatic acute decompensated heart failure.
Tier 1. Nesiritide (recombinant human BNP-32) gained FDA approval in 2001 based on the VMAC trial (acute decompensated heart failure, dyspnoea endpoint). Subsequent ASCEND-HF (Phase 3, ~7000 patients) showed no significant improvement in 30-day all-cause mortality or rehospitalisation versus placebo, reframing nesiritide use. Separately, BNP and NT-proBNP plasma assays (Maisel 2002 Breathing Not Properly Multinational Study and successors) are tier-1 diagnostic and prognostic biomarkers in heart failure.
Nesiritide infusion is associated with hypotension as the principal dose-limiting effect; renal-function concerns raised in early meta-analyses were not substantiated in ASCEND-HF. Short-term safety profile is otherwise favourable. Native BNP biology is not associated with chronic-administration safety questions because the native peptide is not administered as a therapeutic.
Regulatory status
- FDA status:
- FDA-approved
- Compounding:
- Not eligible for compounding (approved, not in shortage)
The 'BNP biomarker vs nesiritide therapeutic' distinction is important - BNP / NT-proBNP measurement is a foundational heart-failure tool, but the recombinant peptide as an acute-decompensated-heart-failure infusion has a more complicated clinical trajectory.
Vendor-sold 'BNP' research peptide is intended for laboratory use as a research reagent or assay calibrator; it is not interchangeable with the licensed nesiritide product (Natrecor).